Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFocusrite Regulatory News (TUNE)

Share Price Information for Focusrite (TUNE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 345.00
Bid: 340.00
Ask: 350.00
Change: 12.50 (3.76%)
Spread: 10.00 (2.941%)
Open: 332.50
High: 345.00
Low: 332.50
Prev. Close: 332.50
TUNE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Secondary Placing of Shares

24 Jan 2019 14:57

RNS Number : 0481O
Focusrite PLC
24 January 2019
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR THE UNITED STATES.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Focusrite plc

("Focusrite" or the "Group")

Completion of Secondary Placing of Shares and

Notification of Director/PCA Dealings

 

Focusrite plc (LSE AIM: TUNE), the global music and audio products company that trades under the Focusrite and Novation brands, is pleased to confirm that, further to the Group's announcement earlier today, Phil Dudderidge (Executive Chairman and Founder) and Jennifer Dudderidge (his closely associated person), have sold shares at 500 pence per sale share in order to satisfy institutional demand from new and existing investors (the "Sale"). In aggregate, 1,468,000 Ordinary Shares were subject to the Sale, representing approximately 2.5% of the Group's issued share capital.

The Group will not receive any proceeds from the Sale. The Sale was executed by Panmure Gordon (UK) Limited ("Panmure Gordon") who is the Company's Nominated Adviser and Broker.

Following the Sale, Phil Dudderidge and Jennifer Dudderidge will together have a beneficial interest in 20,781,000 Ordinary Shares representing 35.8% of the Group's issued share capital. Phil Dudderidge and Jennifer Dudderidge have both agreed with Panmure Gordon that these remaining 20,781,000 Ordinary Shares will be subject to a 6 month orderly market agreement from the date of this notification.

-ends-

 

Enquiries:

 

Focusrite Plc:

Tim Carroll (CEO)

+44 1494 836301

Jeremy Wilson (CFO)

+44 1494 836301

Panmure Gordon

 +44 20 7886 2500

Freddy Crossley / Alina Vaskina

Erik Anderson

Belvedere Communications

+44 20 3687 2756

John West

Kim Van Beeck

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 1

 

Details of the person discharging managerial responsibilities / person closely associated 

a)

 

Names 

1. Phil Dudderidge

2. Jennifer Dudderidge

 

2

 

Reason for the notification

a)

 

Position/status

 

1. Executive Chairman and Founder

2. Person closely associated with Phil Dudderidge

 

 

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

 

Focusrite plc

b)

 

LEI

213800JJ51KA4LOTF736

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Ordinary Shares of 0.1p each

b)

Identification code 

 

GB00BSBMW716

c)

 

Nature of the transaction 

 

 Sale of Ordinary Shares

d)

 

Price(s) and volume(s)

Price(s)

Volume(s)

1. 500p

1. 734,000 Ordinary Shares

2. 500p

2. 734,000 Ordinary Shares

d)

 

Aggregated information 

- Aggregated volume

- Price

 

1,468,000 Ordinary Shares

500p

 

e)

 

Date of the transaction 

24 January 2019

f)

 

Place of the transaction

London Stock Exchange

 

IMPORTANT NOTICE

 

The distribution of this announcement and the offer and sale of the Sale Shares in certain jurisdictions may be restricted by law. The Sale Shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the Sale Shares in such jurisdiction. No action has been taken by Focusrite Plc, Panmure Gordon or any of their respective affiliates that would permit an offering of the Sale Shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required.

 

This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and dependencies, any State of the United States and the District of Columbia), Australia, Canada, Japan or Republic of South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States. There will be no public offer of any securities in the United States or in any other jurisdiction.

 

In member states of the European Economic Area ("EEA") which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer if made subsequently is directed exclusively at persons who are 'qualified investors' within the meaning of the Prospectus Directive ("Qualified Investors"). For these purposes, the expression 'Prospectus Directive' means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression '2010 PD Amending Directive' means Directive 2010/73/EU. In the United Kingdom this announcement is directed exclusively at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) who fall within Article 49(2) (A) to (D) of the Order, or (iii) to whom it may otherwise lawfully be communicated.

 

This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

 

Panmure Gordon is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and is acting exclusively for the Company and the selling shareholders and for no one else in connection with the Sale and will not regard any other person as a client in relation to the Sale and will not be responsible to any other person for providing the protections afforded to its clients nor for providing advice in relation to the Sale or any other matter referred to in this announcement.

 

This document includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "intends", "expects", "will", or "may", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Any forward-looking statements are subject to risks relating to future events and assumptions relating to Focusrite Plc's business, in particular from changes in political conditions, economic conditions, evolving business strategy, or the retail industry. No assurances can be given that the forward-looking statements in this document will be realised. As a result, no undue reliance should be placed on these forward-looking statements as a prediction of actual results or otherwise.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEZZLFLKFFEBBZ
Date   Source Headline
22nd Apr 20246:09 pmRNSTR-1
9th Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20247:00 amRNSNotice of Interim Results
22nd Mar 20243:36 pmRNSNotification of PDMR Transactions
22nd Mar 20248:01 amRNSTR-1
20th Mar 20247:01 amRNSTR-1
19th Mar 20244:44 pmRNSNotification of PDMR Transactions
18th Mar 20247:00 amRNSTrading Update
14th Feb 20243:10 pmRNSNotification of PDMR Transactions
7th Feb 20242:25 pmRNSTR-1
19th Jan 202412:59 pmRNSResult of AGM
19th Jan 20247:00 amRNSAGM Statement
8th Jan 20244:36 pmRNSTR-1
2nd Jan 20247:00 amRNSPHIL DUDDERIDGE AWARDED OBE
19th Dec 20237:00 amRNSAcquisition of Sheriff Technology Limited
7th Dec 20233:58 pmRNSTR-1
5th Dec 20232:02 pmRNSGrant of Share Options to PDMRs
5th Dec 20231:54 pmRNSDirector Share Dealings
29th Nov 20234:51 pmRNSTR-1
28th Nov 20237:00 amRNSFinal Results
17th Nov 202310:27 amRNSTR-1
17th Nov 20237:00 amRNSTR-1
7th Nov 20237:00 amRNSTR-1
31st Oct 20237:00 amRNSNotice of Final Results
14th Sep 20237:00 amRNSTrading Update for the year ended 31 August 2023
9th Jun 202310:54 amRNSNotification of PDMR Transactions
16th May 20237:20 amRNSChange of Registered Office
3rd May 20237:00 amRNSPDMR Dealings
26th Apr 20232:39 pmRNSInterim Dividend Timetable Correction
25th Apr 20237:00 amRNSHalf year results
11th Apr 20231:28 pmRNSNotice of Interim Results
14th Mar 20237:00 amRNSTrading Update
22nd Feb 20239:25 amRNSNotification of PDMR Transactions
7th Feb 20239:51 amRNSPDMR Dealings
3rd Feb 202312:49 pmRNSResult of AGM
3rd Feb 20237:00 amRNSAGM Statement and Update on Trading
18th Jan 20237:00 amRNSSettlement of Share Options
18th Jan 20237:00 amRNSNotification of PDMR Transaction
16th Jan 202311:43 amRNSSettlement of Share Options
22nd Dec 202211:49 amRNSGrant of Share Options to PDMRs
20th Dec 20227:00 amRNSAcquisition of Sonnox Limited
14th Dec 20227:00 amRNSPDMR
8th Dec 20229:05 amRNSSecond Price Monitoring Extn
8th Dec 20229:00 amRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSFinal Results
7th Dec 202211:12 amRNSShare issuance to Employee Benefit Trust
21st Nov 20227:00 amRNSChange to Final Results announcement date
7th Nov 20227:00 amRNSNotice of Final Results
27th Oct 20221:37 pmRNSHolding(s) in Company
3rd Oct 20226:12 pmRNSPDMR Dealings - amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.